Axsome Therapeutics (AXSM) Interest & Investment Income (2015 - 2026)
Axsome Therapeutics recorded quarterly Interest & Investment Income of -$1.2 million in Q1 2026, down 1.11% quarter-over-quarter from -$1.2 million in Q4 2025, and up 51.25% year-over-year from -$783447.1 in Q1 2025.
Axsome Therapeutics' Interest & Investment Income history runs 12 years deep, the most recent figure standing at -$1.2 million for Q1 2026.
- In Q1 2026, Interest & Investment Income rose 51.25% year-over-year to -$1.2 million; the TTM figure through Mar 2026 stood at -$5.3 million (up 32.92% YoY), while the FY2025 annual figure was -$6.6 million, changed 0.18% from the prior year.
- Interest & Investment Income came in at -$1.2 million for Q1 2026 at Axsome Therapeutics, down from -$1.2 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of -$702000.0 in Q4 2023 to a low of -$2.7 million in Q2 2023.
- A 5-year average of -$1.7 million and a median of -$1.3 million in 2022 frame the typical range for Interest & Investment Income.
- Across the five-year window, Interest & Investment Income soared 68.6% in 2023 and slumped 214.81% in 2024, its largest moves.
- Axsome Therapeutics' Interest & Investment Income stood at -$1.3 million in 2022, then soared by 46.94% to -$702000.0 in 2023, then plunged by 214.81% to -$2.2 million in 2024, then surged by 46.97% to -$1.2 million in 2025, then decreased by 1.11% to -$1.2 million in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered -$1.2 million, -$1.2 million, and -$1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Axsome Therapeutics | 11.82 Bn | 11.51 Bn | 176.48 Mn | -1.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.19 Mn |
| Dec 31, 2025 | -1.17 Mn |
| Sep 30, 2025 | -1.12 Mn |
| Jun 30, 2025 | -1.83 Mn |
| Mar 31, 2025 | -2.43 Mn |
| Dec 31, 2024 | -2.21 Mn |
| Sep 30, 2024 | -1.98 Mn |
| Jun 30, 2024 | -1.30 Mn |
| Mar 31, 2024 | -1.08 Mn |
| Dec 31, 2023 | -702,000.00 |
| Sep 30, 2023 | -757,000.00 |
| Jun 30, 2023 | -2.73 Mn |
| Mar 31, 2023 | -2.26 Mn |
| Dec 31, 2022 | -1.32 Mn |
| Sep 30, 2022 | -2.41 Mn |
| Jun 30, 2022 | -2.26 Mn |
| Mar 31, 2022 | -1.34 Mn |
| Dec 31, 2021 | -1.37 Mn |
| Sep 30, 2021 | -1.48 Mn |
| Jun 30, 2021 | -1.44 Mn |
| Mar 31, 2021 | -1.42 Mn |
| Dec 31, 2020 | -1.47 Mn |
| Sep 30, 2020 | -551,002.00 |
| Jun 30, 2020 | -548,158.00 |
| Mar 31, 2020 | 7,311.00 |
| Dec 31, 2019 | -378,814.00 |
| Sep 30, 2019 | -327,825.00 |
| Jun 30, 2019 | -313,995.00 |
| Mar 31, 2019 | -218,903.00 |
| Dec 31, 2018 | -248,700.00 |
| Sep 30, 2018 | -270,933.00 |
| Jun 30, 2018 | -292,323.00 |
| Mar 31, 2018 | -315,349.00 |
| Dec 31, 2017 | -340,381.00 |
| Sep 30, 2017 | -343,234.00 |
| Jun 30, 2017 | -333,578.00 |
| Mar 31, 2017 | -323,006.00 |
| Dec 31, 2016 | -177,657.00 |
| Sep 30, 2016 | 13,219.00 |
| Jun 30, 2016 | 15,090.00 |
| Mar 31, 2016 | 16,924.00 |
| Dec 31, 2015 | -116,403.00 |
| Sep 30, 2015 | -279,802.00 |
| Jun 30, 2015 | -211,062.00 |
| Mar 31, 2015 | -128,781.00 |